Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Vascular Endothelial cell Growth Factor D,VEGF-D ELISA KIT

Human Vascular Endothelial cell Growth Factor D,VEGF-D ELISA KIT

  • 中文名称：
    人血管内皮细胞生长因子D(VEGF-D)酶联免疫试剂盒
  • 货号：
    CSB-E04760h
  • 规格：
    96T/48T
  • 价格：
    ￥3200/￥2500
  • 其他：

产品详情

  • 产品描述：

    The human VEGFD ELISA Kit is intended to measure human VEGFD in serum, plasma, or tissue homogenates. This assay uses the bi-antibody sandwich technique and enzyme-substrate chromogenic reaction to quantify human VEGFD concentration. The intensity of the colored product is directly proportional to the concentration of VEGFD present in the sample. This human VEGFD ELISA kit has high specificity and excellent sensitivity.

    VEGFD is a secreted glycoprotein that can activate VEGFR-2 and VEGFR-3 on the endothelium and acts as a mitogen for endothelial cells to promote the growth and remodeling of blood vessels and lymphatic vessels. VEGFD is a potential biomarker for lymphangioleiomyomatosis. It has been demonstrated that high serum levels of VEGFD are linked to atrial fibrillation, ischemic stroke, and heart failure. Elevated VEGFD values have recently been associated with all-cause mortality in individuals with coronary artery disease.

  • 别名：
    c-fos induced growth factor ELISA Kit; c-fos induced growth factor (vascular endothelial growth factor D) ELISA Kit; c-fos induced growth factor ELISA Kit; c-fos-induced growth factor ELISA Kit; FIGF ELISA Kit; Vascular endothelial growth factor D ELISA Kit; Vascular endothelial growth factor D precursor ELISA Kit; Vascular endothelial growth factor D precursor ELISA Kit; VEGF D ELISA Kit; VEGF-D ELISA Kit; VEGFD ELISA Kit; VEGFD_HUMAN ELISA Kit
  • 缩写：
    FIGF
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, tissue homogenates
  • 检测范围：
    31.25 pg/ml - 2000 pg/ml
  • 灵敏度：
    7.81 pg/ml
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Cardiovascular
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human VEGF-D in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
      Sample Serum(n=4)  
    1:1 Average % 95  
    Range % 88-98  
    1:2 Average % 102  
    Range % 92-106  
    1:4 Average % 98  
    Range % 89-102  
    1:8 Average % 94  
    Range % 87-98  
  • 回收率：
    The recovery of human VEGF-D spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 91 84-96  
    EDTA plasma (n=4) 99 91-103  
                 
                 
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected  
    4000 2.436 2.568 2.502 2.352  
    2000 2.062 2.132 2.097 1.947  
    1000 1.457 1.444 1.451 1.301  
    500 0.760 0.789 0.775 0.625  
    250 0.486 0.458 0.472 0.322  
    125 0.372 0.360 0.366 0.216  
    62.5 0.255 0.247 0.251 0.101  
    0 0.152 0.148 0.150    
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
  • 基因功能参考文献：
    1. SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
    2. Serum VEGF-D levels were significantly increased in definite lymphangioleiomyomatosis (LAM) patients compared with healthy controls. Serum VEGF-D levels were significantly increased in definite LAM patients who had chylothorax compared with those without chylothorax. PMID: 29906075
    3. no difference in the levels of VEGF-A, VEGF-C, and VEGF-D in pre-eclampsia compared to normotensive pregnant women stratified by HIV status PMID: 28524736
    4. CXCR4, CCR7, VEGF-C and VEGF-D expression might have synergistic effects on the lymph node metastasis in patients with cervical cancer. PMID: 28535405
    5. VEGF-D-induced changes in serine/threonine kinase mTOR shuttling between the cytosol and nucleus and its increased phosphorylation at Ser-2448, lead us to the conclusion that the observed shift in redox balance is regulated via mTOR kinase signalling. PMID: 27957793
    6. High VEGFD expression is associated with lymphangioleiomyomatosis. PMID: 28202529
    7. Data show that VEGF-C, VEGF-D, and VEGFR-3 were expressed in a substantial percentage of breast carcinomas. PMID: 28791841
    8. High VEGFD expression is associated with angiogenesis and lymphangiogenesis. PMID: 27852824
    9. VEGF-D and its receptors were co-localized on blood vessels in clinical samples of human lungs exposed to hyperoxia; hence, VEGF-D may act directly on blood vessels to promote fluid leak. PMID: 26924464
    10. VEGF-D-enhanced metastasis was evidently reversed by MP. MP significantly reduced the invasion of VEGFD-SK cells, tumor volume, lymphatic metastasis rates and lymphatic vessel density compared with control groups PMID: 27211072
    11. Sulf2 facilitated lymphangiogenesis in breast cancer cells by regulating VEGF-D and that the AKT1related signaling pathway was involved. PMID: 27748846
    12. Data indicate that vascular endothelial growth factor D (VEGF-D) was the best indicator of metastasis and vascular endothelial growth factors and receptor-3 (VEGFR-3) may help to determine the prognosis and management of colorectal cancer (CRC). PMID: 26476536
    13. Taken together, our data suggest that TNF-alpha can promote lymphangiogenesis and lymphatic metastasis of GBC through the ERK1/2/AP-1/VEGF-D pathway. PMID: 26992854
    14. VEGF-D may play an important role in the process of lymphatic metastasis of epithelial ovarian cancer PMID: 23915006
    15. CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via ERK/Akt pathway in lung cancer. PMID: 26884842
    16. The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: VEGF-C and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3). PMID: 26706909
    17. Study demonstrated that VEGF-D upregulates myofibroblast proliferation, migration, and collagen synthesis through activation of VEGF pathway. PMID: 26724950
    18. MTA1 is up-regulated in CRC; its expression is inversely associated with lymphatic metastases and the expression of VEGFC, VEGFD and VEGFR3 PMID: 26543080
    19. VEGF-C/D score correlated neither with periphery Lymphatic vessel density (LVD) nor with LVD in the tumor center PMID: 26296919
    20. study suggests that both VEGF-C and VEGF-D in tumor cells promote lymph node metastasis PMID: 25911567
    21. A positive association for VEGF-D and an inverse association for MMP-2 were observed in patients with positive lymph node status at the time of radical cystectomy in urothelial carcinoma of the bladder. PMID: 26241709
    22. These findings suggest that IL-8 may be a potent inducer of LECs, although this effect does not appear to involve the VEGF-C/VEGF-D and VEGFR-3 signaling pathway. PMID: 25891418
    23. fluid shear stress induces the synthesis of Insulin growth factor-2 and vascular endothelial growth factor (VEGF) B and D, which in turn transactivate MMP-12. PMID: 25435370
    24. Among VEGF homologs, MMPE from various kinds of tumor origin, VEGF-D showed 92.6% rate of positive expression. ICC stain of VEGF-D is a useful marker in the aid of MMPE diagnosis. PMID: 25221955
    25. The preoperative sVEGF-C/D levels might be reliable biomarkers for the presence of disease and LNM in patients with GBC. The sVEGF-C/D levels may be prognosis factors that can predict a poor outcome for GBC patients PMID: 25801241
    26. VEGF-D is involved in the development of lymphangiogenesis in peritoneal dialysis patients. PMID: 26121315
    27. Both VEGF-C and VEGF-D are highly expressed in esophageal squamous cell cancer tissue, which may be related to the lymph node metastasis of cancer cells. PMID: 25640364
    28. predictive value of VEGF-D expression for bevacizumab may depend on the chemotherapy backbone used PMID: 26125443
    29. Transforming growth factor-beta1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway PMID: 24515257
    30. Increase of VEGFD protein expression is associated with oral squamous cell carcinoma. PMID: 24085575
    31. overexpression of lymphangiogenic factors VEGF-C and VEGF-D in colon adenocarcinoma was associated with increased vessel density in tumor-surrounding stroma. PMID: 24173916
    32. Predictive marker analysis indicated that plasma levels of VEGF-D, Ang2, and SDF1 significantly predicted for benefit or lack of benefit from bevacizumab in this population. PMID: 24097873
    33. VEGF-D promotes lymph node metastasis by increasing tumor lymphangiogenesis, stimulating draining lymphatic vessel formation and enhancing tumor invasiveness. PMID: 24502459
    34. High VEGF-D is associated with gastric cancer. PMID: 23238856
    35. Dysregulated expression of VEGF-D likely contributes to altered angiogenesis, lymphangiogenesis, neurogenesis and immune function in endometriosis. PMID: 23585340
    36. The expression of VEGFR-3 and its ligands, VEGF-C and VEGF-D, significantly increased after activating ET(B)R by ET-1 in primary and metastatic melanoma cell lines PMID: 22965194
    37. Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with tuberous sclerosis complex. PMID: 23437092
    38. Serum vascular endothelial growth factor (VEGF)-D is significantly elevated in patients with lymphangioleiomyomatosis and is a better diagnostic marker than matrix metalloproteinase (MMP)-2, MMP-9 and ACE. PMID: 22513045
    39. The propeptides profoundly influence molecular interactions of VEGF-D with VEGF receptors, co-receptors, and heparin, and its effects on tumor biology. PMID: 23404505
    40. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor D promotes lymph node metastasis in breast cancer. PMID: 22906075
    41. Correlation between intensity of AT-1R expression and expression of lymph- and angiogenesis markers in IDC was examined. Expression intensity of AT-1R was found to correlate with expressions of VEGF-A (r = 0.26; p = 0.008)and VEGF-D (r = 0.24; p = 0.015). PMID: 22581182
    42. Lymphatic microvessel density, VEGF-C and VEGF-D could predict poor prognosis in patients with breast cancer. PMID: 23054001
    43. VEGFD added to the culture medium increased the number of cells expressing tyrosine hydroxylase (a marker for DA neurons) and betaIII-tubulin (a marker for DA neurons) and betaIII-tubulin (a marker for immature neurons) in both the NTera2 and I6 cell lines. PMID: 22535492
    44. results demonstrated that ET-1 and hypoxia act, at list in part, through VEGF to induce lymphangiogenic events and that these two stimuli may cooperate to induce VEGF-A/-C/-D expression and lymphatic differentiation. PMID: 22552325
    45. Differential capacity for VEGF-D production and integrin alpha 9 beta 1 expression by human breast cancer cell line MDA-MB-468LN jointly contributed to their lymphatic metastatic phenotype. PMID: 22545097
    46. VEGF-D has a role in progestin-induced break-through bleeding in thin-walled blood and lymphatic endometrial vessels PMID: 22383980
    47. These data demonstrate that the VEGF-D serum levels are reduced in patients with metastases of differentiated thyroid cancer, regardless of the degree of metastatic spread. PMID: 21781145
    48. A significant relationship was found in salivary gland tumors with myoepithelial differentiation regarding simultaneous positive staining for VEGF-C/VEGF-D and flt-4 PMID: 22326635
    49. Vascular endothelial growth factor D was expressed in 4 of 7 primary and 7 of 7 metastatic lesions. In culture, vascular endothelial growth factor D significantly increased the migration of sarcoma cells through lymphatic endothelial monolayers. PMID: 22326461
    50. VEGF-D is involved and plays an important role in gallbladder cancer (GBC), progression, suggesting that VEGF-D may be a potential molecular target in the treatment of GBC. PMID: 22071224

    显示更多

    收起更多

  • 亚细胞定位：
    Secreted.
  • 蛋白家族：
    PDGF/VEGF growth factor family
  • 组织特异性：
    Highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas.
  • 数据库链接：

    HGNC: 3708

    OMIM: 300091

    KEGG: hsa:2277

    STRING: 9606.ENSP00000297904

    UniGene: Hs.11392